Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Rapid Reviews in Oncology: Clinical Developments in Hematologic Malignancies

Release Date: January 12, 2010| Expiration Date: January 12, 2011
1.75 AMA PRA Category 1 Credit(s)™| Dec 10, 2009, Dallas, TX

Lecture Overview

Treatment options for hematologic malignancies are constantly evolving, leaving medical oncologists and hematologists with a range of treatment decisions further complicated by increasing knowledge on new subtypes of hematologic malignancies. It is imperative that hematologists maintain an extensive knowledge base, including current clinical trial data, to ensure that patients receive the most effective care for their disease.

This activity is from the live Rapid Reviews in Oncology: Clinical Developments in Hematologic Malignancies held on December 10, 2009. The program is designed to update practicing medical oncologists and hematologists on the management of and emerging treatment options for multiple myeloma (MM), myelodysplastic syndromes (MDS), non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL).

The overall objective of this program is to provide updates on options that can be integrated into the current treatment algorithms for patients with hematologic malignancies as well as enhance awareness of novel agents in development to increase the number of patients enrolled in clinical trials.

Target Audience

This program is directed primarily toward medical oncologists and hematologists. Physicians’ assistants, nurses, fellows, pharmacists, and all members of the hematology/oncology field who are interested in the treatment of cancer are also invited to participate.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Discuss emerging agents for previously untreated MM, including immunomodulatory agents, proteasome inhibitors, and novel anthracycline formulations
  • Integrate novel treatment regimens into the management of CLL, including monoclonal antibodies in combination with growth factors, purine analogues, and other targeted agents
  • Analyze the safety and efficacy of immunomodulatory and hypomethylating agents, growth factors, and novel agents for the optimal management of MDS
  • Discuss emerging treatment options for the optimal management of NHLs

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentations and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Complete the test(s) and evaluation by January 12, 2011 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Rapid Reviews in Oncology: Clinical Developments in Hematologic Malignancies program have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Myron S. Czuczman, MD
Research Funding – Biogen Idec, Celgene Corporation, Genmab, GlaxoSmithKline,
  Millennium Pharmaceuticals, Inc.
Paid Consultant – Amgen, Biogen Idec, Celgene Corporation, Genentech, Inc., GlaxoSmithKline,
  Millennium Pharmaceuticals, Inc., Morphosys AG, Novartis Pharma AG

Rafael Fonseca, MD
Research Funding – Cylene Pharmaceuticals, Proteolix, Inc.
Paid Consultant – Amgen, Bristol-Myers Squibb Company, Celgene Corporation,
  Genzyme Corporation, Otsuka Pharmaceutical Co., Ltd.

B. Douglas Smith, MD
Research Funding – Bayer HealthCare AG, Calistoga Pharmaceuticals, Inc., Eisai Inc.,
  Merck Serono International SA, Novartis Pharma AG, Synta Pharmaceuticals Corp.
Paid Consultant – Bristol-Myers Squibb Company, Celgene Corporation

William G. Wierda, MD, PhD
Research Funding – Abbott Laboratories, Bayer Healthcare AG, GlaxoSmithKline, sanofi-aventis U.S.
Paid Consultant – Abbott Laboratories, Genentech, Inc., GlaxoSmithKline,
  Ligand Pharmaceuticals, Inc., MedImmune, Inc., Trubion Pharmaceuticals Inc.
Speaker’s Bureau – Celgene Corporation, Genzyme Corporation
Honoraria – Genentech, Inc.

PER Editorial Staff
No relevant relationships to disclose

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

Commercial Support
An educational grant for this activity was provided by Celgene Corporation and Cephalon Oncology.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Disclaimer
The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2010 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Rapid Reviews in Oncology: Clinical Developments in Hematologic Malignancies
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

8707

Educational Grants

An educational grant for this activity was provided by:


  1. Celgene Corporation
  2. Cephalon Oncology